Financial Highlights for 2024:

• Revenue amounted to DKK 7.37 million, reflecting a year-over-year increase of 21.4% (2023: DKK 6.07 million).

 

• Sales volumes reached 17,027 units, up 18.5% from the prior year (2023: 14,366 units).

 

• EBITDA improved markedly, reducing the deficit by 60.2% to DKK -5.13 million (2023: DKK -12.89 million).

 

• The Company secured financing of approximately 26.3 MDKK (gross), including both debt conversion and capital raising.

 

• As a result, the net financing for 2024 amounted to approximately 6.7 MDKK, while the Company’s debt positions were fully reset, leaving it debt-free by the end of the financial year.

 

• Cash position as of 31 December 2024 strengthened to DKK 3.47 million.

 

Key Strategic and Operational Highlights in 2024:

• The Company successfully continued its strategic transition towards a lean, asset-light model, focusing on sourcing, importing, and distributing cannabinoid-based medicines.

 

• Solid growth in the core Rx portfolio for prescribed cannabinoid therapies.

 

• Significant progress in pipeline development, with submissions for multiple new products to the Danish Medicines Agency, and preparations for entry into the OTC segment.

 

• Confirmation of the permanent status of the Danish Pilot Programme for medicinal cannabis, ensuring long-term market stability and validating the therapeutic potential of cannabinoids.

Outlook for 2025:

• The Company anticipates continued momentum with guidance for 2025 revenue in the range of DKK 10.0 to 12.5 million and targeted EBITDA of DKK -4.0 to -6.0 million.

 

• Expansion of product offerings in both Rx and OTC segments expected to drive further market penetration and diversification.

 

• Ongoing pursuit of operational efficiencies and enhanced shareholder value creation through disciplined capital allocation and market-focused initiatives.

 

 

For further information, please contact:

Jeppe Krog Rasmussen, CEO

E-mail: jkr@dancann.com

 

About DanCann Pharma A/S

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical Company powered by cannabinoids. 

DanCann Pharma A/S (SS: DANCAN) is listed on the Spotlight Stock Market in Copenhagen/Stockholm.

 

For more information, visit: www.dancann.com

 

 

Forward-looking-statement:

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events, or developments that the Company believes, expects, or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology.

 

Forward-looking statements are subject to several risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities.

 

Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this presentation are made as of the date of this presentation and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

 

This disclosure contains information that DanCann Pharma A/S is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 04-04-2025.